Genex Pharmaceutical, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GENX research report →
About the company
Genex Pharmaceutical, Inc. engages in the development and production of Reconstituted Bone Xenograft, which is a medical device that accelerates bone healing. The company was founded on February 28, 2002 and is headquartered in Tianjin, China.
- CEO
- Fuzhi Song
- IPO
- 2004
- Employees
- 86
- HQ
- Tianjin, TX, CN
Price Chart
- Market Cap
- $1.79K
- P/E
- 0.01
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -0.54
- Div Yield
- 0.00%
- Gross Margin
- 88.80%
- Op Margin
- 14.40%
- Net Margin
- 10.58%
- ROE
- 7.78%
- ROIC
- 4.21%
- Revenue
- $3.24M · 32.77%
- Net Income
- $342.55K · -44.66%
- EPS
- $0.02 · -36.00%
- Op Income
- $466.14K
- FCF YoY
- -55.09%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.47
- Avg Volume
- 19
Get TickerSpark's AI analysis on GENX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our GENX coverage
Recent articles, reports, and earnings notes.
No research on GENX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GENX report →Similar companies
Peers in the same neighborhood.